Amneal Pharma Bets Big On Biosimilars Growth

Amneal Pharma ((AMRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Amneal Pharma’s latest earnings call struck an optimistic tone, as management balanced strong current execution with a bold strategic bet on biosimilars. The Kashiv BioSciences acquisition was framed as transformational, extending Amneal’s reach, scale and vertical integration, while Q1 results showed solid growth, margin expansion and improving leverage that together underpin a more compelling long‑term story.

Strategic Acquisition Creating a Global Biosimilars Platform

Amneal unveiled a $750 million deal to acquire Kashiv BioSciences, split evenly between cash and equity and implying roughly 8% dilution for current shareholders. The combination creates a vertically integrated biosimilars platform with more than 20 programs and exposure to over $300 million in expected biologic loss‑of‑exclusivity opportunities within a decade, tapping into a U.S. market above $100 billion.

Robust Q1 2026 Financial Performance

Preliminary Q1 numbers showcased solid momentum, with total net revenue of $723 million, up 4% year over year, and adjusted EBITDA rising 19% to $202 million. Adjusted EPS climbed 29% to $0.27, powered by steady 2% growth in the Affordable Medicines segment and a strong 23% jump in Specialty revenue to $133 million.

Margin Expansion and Operating Leverage

Profitability was a highlight, as Affordable Medicines posted a 47.3% gross margin, up 320 basis points from the prior year’s quarter. Overall adjusted gross margins expanded about 500 basis points, prompting management to lift its full‑year 2026 gross margin target to roughly 45%, around 200 basis points above 2025 and signaling ongoing operating leverage.

Pipeline and Launch Cadence

Management outlined an ambitious biosimilar launch schedule, targeting six commercial biosimilars by 2027, including Avastin and Denosumab, while XOLAIR remains pending approval. Beyond those, lanreotide is expected to secure approval in the third quarter, XOLAIR is eyed for sign‑off by year‑end, and at least six additional advanced programs are slated for approval by 2030.

Manufacturing Capacity and Scalability

Kashiv brings four R&D and manufacturing facilities and about 600 employees, backed by more than $900 million of historical investment in biologics infrastructure. Amneal plans to ramp drug‑substance capacity from 26,000 liters in 2026 to 75,000 liters by 2028, supported by roughly $30 million to $50 million of annual capital spending over the next two to three years.

Financial Synergies and Long-Term Growth Targets

The company is targeting $400 million to $500 million in cumulative synergies from the Kashiv combination, spanning cost efficiencies and revenue opportunities. By 2030, Amneal expects revenue to reach $4.3 billion to $4.5 billion, roughly 40% above 2026, while EPS is projected to rise by around $0.70, or about 70%, with biosimilars contributing $1.0 billion to $1.3 billion.

Improving Leverage Despite Deal Funding

Leverage trends are improving, with net debt at 3.5 times adjusted EBITDA as of March 2026, down from 3.9 times a year earlier. While the Kashiv transaction is projected to lift combined net leverage to about 3.7 times by the end of 2026, management outlined a trajectory to reduce that level to below 3 times by 2028 as earnings grow.

Specialty Launch Momentum

Specialty products are gaining traction, with CREXONT generating $21 million in Q1 revenue and supported by favorable Phase IV data that could sustain uptake. Newly launched Brekiya also accelerated, posting $4.6 million in Q1 sales compared with $1.6 million in the fourth quarter of 2025, signaling rapid physician adoption and growing brand recognition.

Near-Term Leverage Increase and Transaction Costs

Management acknowledged that funding the Kashiv deal through a blend of cash and additional debt will nudge leverage higher in the short term and bring near‑term transaction and integration costs. However, they emphasized that deleveraging should resume after 2026 as synergies materialize, setting the stage for a more conservative balance sheet by 2028.

Upfront Dilution and Contingent Consideration

The equity component of the purchase, about $29 million in Amneal shares, equates to roughly 8% dilution and will immediately expand the share base. Additional milestone payments of up to $350 million and potential royalties introduce future cash and earnings variability, tightly linked to the success of pipeline approvals and commercial performance.

2027 Guidance and Near-Term Growth Pace

Updated 2027 guidance calls for adjusted EBITDA of about $820 million, implying around 9% growth over the midpoint of 2026 expectations, a pace some investors may view as cautious. Management attributed this to modest near‑term dilution from the transaction, positioning 2028 and beyond as the period when earnings accretion and stronger growth should be more visible.

Q1 / Full-Year Gross Margin Normalization Risk

Executives cautioned that Q1 margin levels should not be straight‑lined through the year, as the quarter benefitted from particularly strong mix and operational performance. While the implied Q1 run rate approached the high‑40% range, management reiterated a more conservative full‑year gross margin goal near 45%, suggesting some normalization as the year progresses.

Operational and Execution Complexity

The move deeper into biosimilars brings meaningful execution risk, since end‑to‑end biologics R&D and manufacturing involve long lead times and strict regulation. Each biosimilar program can cost an estimated $50 million to $75 million and take five to seven years to develop, making disciplined capital allocation and integration execution critical to the strategy’s success.

AvKARE Revenue Mix Shift

Within the AvKARE business, Q1 revenue declined by $6 million or 4% year over year as Amneal deliberately deemphasized lower‑margin distribution activities. That mix shift pressured the top line but improved profitability, with AvKARE’s gross margin rising about 690 basis points, underscoring management’s focus on quality of revenue over sheer volume.

Guidance and Long-Term Outlook

Amneal raised its stand‑alone 2026 outlook on the back of Q1 outperformance and now targets company‑wide gross margins around 45%, with a longer‑term goal in the mid‑ to high‑40s. Looking further out, the combined Amneal‑Kashiv entity is forecast to reach $4.3 billion to $4.5 billion in revenue and substantially higher EPS by 2030, as biosimilars scale to over $1 billion in annual sales and leverage trends continue to improve.

The earnings call painted a picture of a company in transition, using solid current performance to fund a major push into higher‑value biosimilars. While investors must weigh near‑term dilution, elevated capex and integration risks, the expanded pipeline, capacity build‑out and synergy potential position Amneal for higher growth and profitability over the rest of the decade.